Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B EBIT

The latest EBIT for TCBIO is $560M as of September 2026. That compares with $390M in the prior-year period — up 44.5% year over year. That is below the Finance sector average of $27T. Investors often review this figure alongside Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B's historical trend and sector peers before judging valuation or financial health.

Over the past year, TCBIO's EBIT moved from $390M to $560M — a 44.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B's operating scale or balance-sheet position.

Against Finance companies, TCBIO currently prints $560M for EBIT, while the sector average sits near $27T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Texas Capital Bancshares - 5.75% PRF PERPETUAL USD 25 - Ser B's growth, margins, and balance sheet.

A EBIT figure of $560M for TCBIO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Finance average is about $27T. Explore the charts below for those layers of context.

After noting TCBIO's EBIT ($560M), review year-over-year change from $390M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.